Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells $152,408.71 in Stock

Insider selling refers to the practice of insiders, such as company executives or directors, selling their shares in a publicly traded company. This can be done for various reasons, including raising capital, diversifying their investment portfolio, or simply cashing out some of their holdings.

In this case, James R. Kasinger, the general counsel of CRISPR Therapeutics AG NASDAQCRSP, sold 1,913 shares of the company's stock on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71.

It is important to note that insider selling can have an impact on the stock price of the company, as it can signal to investors that the insiders are not confident in the future prospects of the company. However, it is also worth noting that insider selling does not necessarily mean that the insiders are bearish on the company's future performance. It is simply a matter of them choosing to sell some of their holdings for various reasons.

Following the completion of the sale, the general counsel now holds 10,587 shares of CRISPR Therapeutics stock, which represents approximately 0.2% of the company's outstanding shares. It is worth noting that insiders are subject to certain restrictions on when and how they can sell their shares, as well as requirements to disclose their transactions to the public.